IP3R Modulation by Cancer Genes in Mesothelioma

June 5, 2018 updated by: Yserbyt Jonas, KU Leuven

IP3R Modulation by Cancer Genes Bcl-2 & PKM2 in Mesothelioma

Obtaining pleural biopsies in cases of malignant mesothelioma to detect molecular mechnisms and signal transduction

Study Overview

Status

Not yet recruiting

Conditions

Malignant Mesothelioma

Intervention / Treatment

Diagnostic test: pleural biopsy

Study Type

Observational

Enrollment (Anticipated)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Jonas Yserbyt
Phone Number: +32 16 34 68 01
Email: jonas.yserbyt@uzleuven.be

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 89 years (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

mesothelioma

Description

Inclusion Criteria:

suspicion of mesothelioma
referral for diagnostic thoracoscopy

Exclusion Criteria:

contra-indication for thoracoscopy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pleural biopsy Time Frame: 5 years	Biopsy	5 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunoblotting Time Frame: 5 years	biopsy	5 years
Cytometric analysis (FACS-based approaches) Time Frame: 5 years	biopsy	5 years
Live cell imaging for Ca2+-signaling Time Frame: 5 years	biopsy	5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

KU Leuven

Investigators

Principal Investigator: Jonas Yserbyt, Catholic University Leuven

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

January 1, 2019

Primary Completion (Anticipated)

December 1, 2023

Study Completion (Anticipated)

June 1, 2024

Study Registration Dates

First Submitted

May 23, 2018

First Submitted That Met QC Criteria

June 5, 2018

First Posted (Actual)

June 15, 2018

Study Record Updates

Last Update Posted (Actual)